A share price of NovoCure Ltd [NVCR] is currently trading at $14.64, up 12.01%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVCR shares have gain 7.41% over the last week, with a monthly amount drifted -10.18%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, March 2024, METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer. In a post published today on Yahoo Finance, The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone.
From an analyst’s perspective:
Previously, H.C. Wainwright downgraded its rating to Neutral on August 28, 2023, and dropped its price target to $25. On August 08, 2023, upgrade upgraded it’s rating to Overweight but maintained its price target of $45 on the stock. SVB Securities started tracking the stock assigning a Outperform rating and suggested a price target of $51 on August 04, 2023. Evercore ISI upgraded its rating to a In-line but $33 remained the price target by the analyst firm on July 31, 2023. Wedbush upgraded its rating to Neutral for this stock on June 07, 2023, and downed its price target to $46. In a note dated May 16, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $70 to $104.
NovoCure Ltd experienced fluctuations in its stock price throughout the past year between $10.87 and $83.60. Currently, Wall Street analysts expect the stock to reach $107.5 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $14.64 at the most recent close of the market. An investor can expect a potential return of 634.29% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
Trailing Twelve Months sales for NovoCure Ltd [NASDAQ:NVCR] were 509.34M which represents 4.17% growth. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.52 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.19 points at the first support level, and at 11.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.81, and for the 2nd resistance point, it is at 16.99.
NovoCure Ltd [NVCR] reported earnings per share of -$0.45 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.52/share, meaning a difference of $0.07 and a surprise factor of 13.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.46 per share as compared to estimates of -$0.52 per share, a difference of $0.06 representing a surprise of 11.50%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NovoCure Ltd [NASDAQ:NVCR] is 5.78. In addition, the Quick Ratio stands at 5.56 and the Cash Ratio stands at 1.34. Considering the valuation of this stock, the price to sales ratio is 3.08, the price to book ratio is 4.32.
Transactions by insiders
Recent insider trading involved GROENHUYSEN WILHELMUS CM, Chief Operating Officer, that happened on Mar 04 ’24 when 1217.0 shares were sold. EVP, Pres., Novocure Oncology, Leonard Frank X completed a deal on Mar 04 ’24 to sell 840.0 shares. Meanwhile, Chief Operating Officer GROENHUYSEN WILHELMUS CM sold 2107.0 shares on Mar 01 ’24.
